R2P2 is part of the ReVAMPP research network.

We are a proactive collaborative consortium focused on developing generalizable strategies for safe and effective vaccines and monoclonal antibodies to combat high-priority pathogens most likely to threaten human health.

The work of R2P2 weaves together structural virology, immunology, and machine learning approaches to interrogate four “most-wanted” viral families: respiroviruses, rubulaviruses, peribunyaviruses, and phenuiviruses. Our innovative and synergistic approach will pay off in greatly enhanced agility to rapidly respond to emergent viral outbreaks.